menu search

CANSF / Willow Biosciences secures contracts valued at $1M during 2Q

Willow Biosciences secures contracts valued at $1M during 2Q
Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in near-term research and development (R&D)/milestone revenue and, if successful, will generate long-term commercial revenue. Additionally, the biotechnology company, in collaboration with its partner Sandhill One, initiated the scale-up development of ursodeoxycholic acid to be used in nutraceutical and pharmaceutical products. Read More
Posted: Aug 9 2023, 08:37
Author Name: Proactive Investors
Views: 111030

CANSF News  

Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation

By Proactive Investors
October 3, 2023

Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has partnered with Spanish life science company Suanfarma to bring sustainably source more_horizontal

Willow Biosciences announces $1.2M debt offering

By Proactive Investors
September 12, 2023

Willow Biosciences announces $1.2M debt offering

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a non-brokered private placement offering of convertible debenture units, with the goal of ra more_horizontal

Willow Biosciences completes R&D to produce ursodeoxycholic acid

By Proactive Investors
September 6, 2023

Willow Biosciences completes R&D to produce ursodeoxycholic acid

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic more_horizontal

Willow Biosciences files patent application for process to produce much cheaper corticosteroids

By Proactive Investors
August 30, 2023

Willow Biosciences files patent application for process to produce much cheaper corticosteroids

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has filed a patent application for a process it has developed to produce corticostero more_horizontal

Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform

By Proactive Investors
August 24, 2023

Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced it has engaged an advisor to assist it with a review of opportunities to enhance value for it more_horizontal

Willow Biosciences shares take off on biopharma manufacturing collaboration announcement

By Proactive Investors
August 21, 2023

Willow Biosciences shares take off on biopharma manufacturing collaboration announcement

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF)' Canadian-listed shares had added more than 23% in the early afternoon on Monday after it announced th more_horizontal

Willow Biosciences announces collaboration with Nasdaq-listed biopharma

By Proactive Investors
August 21, 2023

Willow Biosciences announces collaboration with Nasdaq-listed biopharma

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainab more_horizontal

Willow Biosciences secures contracts valued at $1M during 2Q

By Proactive Investors
August 9, 2023

Willow Biosciences secures contracts valued at $1M during 2Q

Willow Biosciences told investors that during the second quarter, it closed three new contracts that are expected to bring in more than $1 million in more_horizontal


Search within

Pages Search Results: